Amyotrophic Lateral Sclerosis Treatment Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The global ALS treatment market is currently estimated at roughly USD 1.2 billion in 2025 and is forecast to expand at a compound annual growth rate near 7.5% through the early 2030s. Revenue is concentrated in the United States and other major pharmaceutical markets, where premium-priced disease-modifying therapies account for the bulk of sales. The market covers both small-molecule drugs and a fast-growing pipeline of gene-targeted and biologic therapies.

• •Market value in 2025 is approximately USD 1.2 billion with a ~7.5% CAGR.
• •North America dominates revenue due to higher drug prices and reimbursement coverage.
• •Approved therapies include riluzole, edaravone, and AMX0035, with several new mechanisms in late-stage trials.

Rising ALS incidence and improved diagnosis are expanding the eligible patient population, while new high-cost therapies such as AMX0035 and AMX004 (sodium phenylbutyrate/taurursodiol follow-on programs) are lifting average treatment value per patient. Regulatory incentives including orphan drug designation and accelerated approval pathways are shortening time-to-market for novel candidates. Expanding reimbursement in the U.S., EU, and Japan is also converting previously off-label or cash-pay use into commercial revenue.

• •Increasing global ALS prevalence and better diagnostic awareness are widening the treated population.
• •Orphan drug status and accelerated approvals are speeding launches of pipeline therapies.
• •Broader reimbursement for newer disease-modifying drugs is boosting per-patient revenue.

By treatment type, the market is split between approved small-molecule drugs (riluzole, edaravone, AMX0035) and pipeline-stage gene therapies, antisense oligonucleotides, and supportive care. By distribution channel, hospital pharmacies lead because most ALS drugs are specialty or infused products, followed by retail and online pharmacies. Regionally, North America holds the largest share, with Europe second and Asia-Pacific the fastest-growing region as Japan and South Korea expand ALS specialty care.

• •Small-molecule drugs lead current revenue; gene therapies and ASOs represent the fastest-growing segment.
• •Hospital pharmacies dominate distribution given the specialty nature of ALS therapies.
• •Asia-Pacific is the fastest-growing region, supported by Japan’s strong ALS specialty infrastructure.

What are the recent trends and outlook?

The next several years are expected to be defined by the launch of gene-targeted therapies, including Tofersen for SOD1-ALS and follow-on ASO programs, which could materially expand the market. Combination therapies pairing neuroprotective small molecules with genetic treatments are an increasing focus of late-stage trials. Precision medicine approaches, including biomarker-based patient stratification and earlier genetic diagnosis, are likely to support premium pricing and broader adoption through 2030 and beyond.

• •Antisense oligonucleotide and gene-therapy launches are expected to reshape market value through 2030.
• •Combination regimens pairing neuroprotective drugs with genetic therapies are a key trial focus.
• •Biomarker-driven patient selection is supporting premium pricing and earlier treatment initiation.